Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

News

News
Ustekinumab Shows Superior Persistance in CD Patients With Prior Biologic Use
08/26/2024
When used after a first-line agent, ustekinumab had significantly better persistence than other biologics.
When used after a first-line agent, ustekinumab had significantly better persistence than other biologics.
When used after a first-line...
08/26/2024
Advances in Inflammatory Bowel Disease Network
News
Upadacitinib Provides Rapid Response in Crohn's Disease
08/12/2024
Pooled data from induction trials showed improvement in symptoms of Crohn’s disease within a week.
Pooled data from induction trials showed improvement in symptoms of Crohn’s disease within a week.
Pooled data from induction...
08/12/2024
Advances in Inflammatory Bowel Disease Network
News
Upadacitinib vs Tofacitinib for Clinical Remission in Ulcerative Colitis
08/09/2024
Investigators conducted a head-to-head trial of the 2 JAK inhibitors to determine which performed best in achieving steroid-free clinical remission among patients with ulcerative colitis
Investigators conducted a head-to-head trial of the 2 JAK inhibitors to determine which performed best in achieving steroid-free clinical remission among patients with ulcerative colitis
Investigators conducted a...
08/09/2024
Advances in Inflammatory Bowel Disease Network

Advertisement

News
Colorectal Cancer Risk Higher Among Patients WIth PSC, With or Without IBD
07/24/2024
Extended screening and surveillance are recommended for all patients with primary sclerosing cholangitis, but those with comorbid inflammatory bowel disease are at highest risk.
Extended screening and surveillance are recommended for all patients with primary sclerosing cholangitis, but those with comorbid inflammatory bowel disease are at highest risk.
Extended screening and...
07/24/2024
Gastroenterology
News
Biomarker Study Finds ‘Clearcut’ Case for Early Advanced Therapy for CD
05/24/2024

Jolynn Tumolo

Jolynn Tumolo
Top-down therapy significantly outperforms step-up treatment for Crohn’s disease with fewer adverse events.
Top-down therapy significantly outperforms step-up treatment for Crohn’s disease with fewer adverse events.
Top-down therapy significantly...
05/24/2024
Advances in Inflammatory Bowel Disease Network
fecal calprotectin test
News
Fecal Calprotectin: Effective Marker In Understanding Progression of Crohn's Disease
05/09/2024

Priyam Vora, Associate Editor

Priyam Vora, Associate Editor
Evidence shows the value of fecal calprotectin to better understand the trajectory of Crohn's disease.
Evidence shows the value of fecal calprotectin to better understand the trajectory of Crohn's disease.
Evidence shows the value of...
05/09/2024
Advances in Inflammatory Bowel Disease Network

Advertisement

News
Study Finds Higher-Than-Expected IBD Rates in US Black Women
05/02/2024

Jolynn Tumolo

Jolynn Tumolo
The incidence of inflammatory bowel disease was highest among Black women younger than 30 years of age.
The incidence of inflammatory bowel disease was highest among Black women younger than 30 years of age.
The incidence of inflammatory...
05/02/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Subcutaneous Vedolizumab for Maintenance Therapy in Crohn’s Disease
04/22/2024
The US Food and Drug Administration approved a subcutaneous formulation of vedolizumab for moderate to severe Crohn's disease.
The US Food and Drug Administration approved a subcutaneous formulation of vedolizumab for moderate to severe Crohn's disease.
The US Food and Drug...
04/22/2024
Advances in Inflammatory Bowel Disease Network
Bharati Kochar
Conference Coverage
Bharati Kochar, MD, on Comparative Effectiveness in Positioning Therapies in Ulcerative Colitis
04/10/2024
Dr Bharati Kochar talks about considering the efficacy-safety relationship to avoid longstanding corticosteroid use or the use of less effective agents in biologic-exposed populations at the AIBD regional meeting in Boston.
Dr Bharati Kochar talks about considering the efficacy-safety relationship to avoid longstanding corticosteroid use or the use of less effective agents in biologic-exposed populations at the AIBD regional meeting in Boston.
Dr Bharati Kochar talks about...
04/10/2024
Advances in Inflammatory Bowel Disease Network

Advertisement

News
Post-Menopausal Women With IBD and Hormone Replacement Therapy
04/05/2024

Priyam Vora, Associate Editor

Priyam Vora, Associate Editor
Investigators sought to determine the effects of hormone replacement therapy on disease activity among post-menopausal women with IBD.
Investigators sought to determine the effects of hormone replacement therapy on disease activity among post-menopausal women with IBD.
Investigators sought to...
04/05/2024
Advances in Inflammatory Bowel Disease Network

Advertisement

Latest News

News
Ustekinumab Shows Superior Persistance in CD Patients With Prior Biologic Use
08/26/2024
When used after a first-line agent, ustekinumab had significantly better persistence than other biologics.
When used after a first-line agent, ustekinumab had significantly better persistence than other biologics.
When used after a first-line...
08/26/2024
Advances in Inflammatory Bowel Disease Network
News
Upadacitinib Provides Rapid Response in Crohn's Disease
08/12/2024
Pooled data from induction trials showed improvement in symptoms of Crohn’s disease within a week.
Pooled data from induction trials showed improvement in symptoms of Crohn’s disease within a week.
Pooled data from induction...
08/12/2024
Advances in Inflammatory Bowel Disease Network
News
Colorectal Cancer Risk Higher Among Patients WIth PSC, With or Without IBD
07/24/2024
Extended screening and surveillance are recommended for all patients with primary sclerosing cholangitis, but those with comorbid inflammatory bowel disease are at highest risk.
Extended screening and surveillance are recommended for all patients with primary sclerosing cholangitis, but those with comorbid inflammatory bowel disease are at highest risk.
Extended screening and...
07/24/2024
Gastroenterology
News
Biomarker Study Finds ‘Clearcut’ Case for Early Advanced Therapy for CD
05/24/2024

Jolynn Tumolo

Jolynn Tumolo
Top-down therapy significantly outperforms step-up treatment for Crohn’s disease with fewer adverse events.
Top-down therapy significantly outperforms step-up treatment for Crohn’s disease with fewer adverse events.
Top-down therapy significantly...
05/24/2024
Advances in Inflammatory Bowel Disease Network
fecal calprotectin test
News
Fecal Calprotectin: Effective Marker In Understanding Progression of Crohn's Disease
05/09/2024

Priyam Vora, Associate Editor

Priyam Vora, Associate Editor
Evidence shows the value of fecal calprotectin to better understand the trajectory of Crohn's disease.
Evidence shows the value of fecal calprotectin to better understand the trajectory of Crohn's disease.
Evidence shows the value of...
05/09/2024
Advances in Inflammatory Bowel Disease Network
News
Study Finds Higher-Than-Expected IBD Rates in US Black Women
05/02/2024

Jolynn Tumolo

Jolynn Tumolo
The incidence of inflammatory bowel disease was highest among Black women younger than 30 years of age.
The incidence of inflammatory bowel disease was highest among Black women younger than 30 years of age.
The incidence of inflammatory...
05/02/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Subcutaneous Vedolizumab for Maintenance Therapy in Crohn’s Disease
04/22/2024
The US Food and Drug Administration approved a subcutaneous formulation of vedolizumab for moderate to severe Crohn's disease.
The US Food and Drug Administration approved a subcutaneous formulation of vedolizumab for moderate to severe Crohn's disease.
The US Food and Drug...
04/22/2024
Advances in Inflammatory Bowel Disease Network
Bharati Kochar
Conference Coverage
Bharati Kochar, MD, on Comparative Effectiveness in Positioning Therapies in Ulcerative Colitis
04/10/2024
Dr Bharati Kochar talks about considering the efficacy-safety relationship to avoid longstanding corticosteroid use or the use of less effective agents in biologic-exposed populations at the AIBD regional meeting in Boston.
Dr Bharati Kochar talks about considering the efficacy-safety relationship to avoid longstanding corticosteroid use or the use of less effective agents in biologic-exposed populations at the AIBD regional meeting in Boston.
Dr Bharati Kochar talks about...
04/10/2024
Advances in Inflammatory Bowel Disease Network
News
Post-Menopausal Women With IBD and Hormone Replacement Therapy
04/05/2024

Priyam Vora, Associate Editor

Priyam Vora, Associate Editor
Investigators sought to determine the effects of hormone replacement therapy on disease activity among post-menopausal women with IBD.
Investigators sought to determine the effects of hormone replacement therapy on disease activity among post-menopausal women with IBD.
Investigators sought to...
04/05/2024
Advances in Inflammatory Bowel Disease Network
News
Extended Mirikizumab Induction Benefits Slower Responders in UC Trials
03/20/2024

Jolynn Tumolo

Jolynn Tumolo
LUCENT trials found that 24-week induction period generated response in half of patients.
LUCENT trials found that 24-week induction period generated response in half of patients.
LUCENT trials found that 24-week...
03/20/2024
Advances in Inflammatory Bowel Disease Network

Advertisement

Latest Podcasts

IBD Drive time logo
Podcast
IBD Drive Time: Dr Jana Al Hashash on Diet and Nutrition in IBD Care
08/05/2024
Dr Jana Al Hashash from Mayo Clinic—Florida offers guidance on how diet can affect IBD and the best approaches to maintaining adequate nutrition, along with hosts Millie Long, MD, and Raymond Cross, MD.
Dr Jana Al Hashash from Mayo Clinic—Florida offers guidance on how diet can affect IBD and the best approaches to maintaining adequate nutrition, along with hosts Millie Long, MD, and Raymond Cross, MD.
Dr Jana Al Hashash from Mayo...
08/05/2024
Advances in Inflammatory Bowel Disease Network
Shubha Bhat
Podcast
Shubha Bhat, PharmD, on the Role of the Clinical Pharmacist in IBD
07/25/2024
Dr Bhat reports on the recent systematic review and RAND consensus process to define the role of the clinical pharmacist in caring for patients with inflammatory bowel disease.
Dr Bhat reports on the recent systematic review and RAND consensus process to define the role of the clinical pharmacist in caring for patients with inflammatory bowel disease.
Dr Bhat reports on the recent...
07/25/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: The Best of DDW, Part 2
07/18/2024
In part 2 of this podcast, cohost Dr Millie Long discusses her picks for the "Best of DDW" on inflammatory bowel disease with her cohost, Dr Ray Cross.
In part 2 of this podcast, cohost Dr Millie Long discusses her picks for the "Best of DDW" on inflammatory bowel disease with her cohost, Dr Ray Cross.
In part 2 of this podcast,...
07/18/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Best of DDW, Part 1
07/09/2024
In the first episode of this two-part series, Dr Raymond Cross of Mercy Medical Center reviews his top picks for the best abstracts on inflammatory bowel disease presented at this year's Digestive Disease Week with cohost Dr Millie Long of...
In the first episode of this two-part series, Dr Raymond Cross of Mercy Medical Center reviews his top picks for the best abstracts on inflammatory bowel disease presented at this year's Digestive Disease Week with cohost Dr Millie Long of...
In the first episode of this...
07/09/2024
Advances in Inflammatory Bowel Disease Network
Millie Long
Video
Millie Long, MD, on Comparative Effectiveness in Ulcerative Colitis
06/24/2024
Dr Long reviews her presentation from the AIBD regional meeting on using comparative effectiveness data to choose from among the growing number of therapies for treating ulcerative colitis.
Dr Long reviews her presentation from the AIBD regional meeting on using comparative effectiveness data to choose from among the growing number of therapies for treating ulcerative colitis.
Dr Long reviews her presentation...
06/24/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: The Best of ECCO With Dr Frank Farraye
06/12/2024
Dr Frank Farraye, director of the IBD Center at Mayo Jacksonville, joins IBD Drive Time hosts Millie Long, MD, and Raymond Cross, MD, to review the best of presentations on the natural history of IBD at the European Crohn's & Colitis...
Dr Frank Farraye, director of the IBD Center at Mayo Jacksonville, joins IBD Drive Time hosts Millie Long, MD, and Raymond Cross, MD, to review the best of presentations on the natural history of IBD at the European Crohn's & Colitis...
Dr Frank Farraye, director of...
06/12/2024
Advances in Inflammatory Bowel Disease Network
Rishika Chugh
Podcast
Rishika Chugh, MD: Safety of Vedolizumab and Ustekinumab in Pregnancy
05/28/2024
Dr Chugh reviews the results of a recent study of the safety of ustekinumab and vedolizumab among pregnant patients with inflammatory bowel disease.
Dr Chugh reviews the results of a recent study of the safety of ustekinumab and vedolizumab among pregnant patients with inflammatory bowel disease.
Dr Chugh reviews the results of...
05/28/2024
Advances in Inflammatory Bowel Disease Network
Noa Cleveland
Podcast
Noa Krugliak Cleveland, MD, on Intestinal Ultrasound in Clinical Practice
05/22/2024
Dr Krugliak Cleveland reviews the results of research and real-world experience in using intestinal ultrasound in clinical practice when diagnosing and monitoring inflammatory bowel disease.
Dr Krugliak Cleveland reviews the results of research and real-world experience in using intestinal ultrasound in clinical practice when diagnosing and monitoring inflammatory bowel disease.
Dr Krugliak Cleveland reviews...
05/22/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Gary Lichtenstein, MD, on the Best of ECCO
05/06/2024
IBD Drive Time continues its coverage of the European Crohn's & Colitis Organization meeting as Dr Gary Lichtenstein shares his choices on the best abstracts with host Dr Raymond Cross.
IBD Drive Time continues its coverage of the European Crohn's & Colitis Organization meeting as Dr Gary Lichtenstein shares his choices on the best abstracts with host Dr Raymond Cross.
IBD Drive Time continues its...
05/06/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
Siddharth Singh: AGA Guidelines on Using Biomarkers in Ulcerative Colitis
04/25/2024
In this episode of IBD Drive Time, cohost Raymond Cross, MD, talks with Siddharth Singh, MD, about the latest guidelines from the American Gastroenterological Association on caring for patients with ulcerative colitis.
In this episode of IBD Drive Time, cohost Raymond Cross, MD, talks with Siddharth Singh, MD, about the latest guidelines from the American Gastroenterological Association on caring for patients with ulcerative colitis.
In this episode of IBD Drive...
04/25/2024
Advances in Inflammatory Bowel Disease Network

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use